مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

244
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

83
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

THE ROLE OF INTERMITTENT CHEMOTHERAPY IN THE SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER

Pages

  21-23

Abstract

 Introduction: PROSTATE CANCER is one of the most common cancers among males and the second factor resulting to death due to cancer among them. (1) The median age of its diagnosis is 65 years. The initial treatment includes androgen ablation or orchiectomy. (2, 3) In case of patient’s hormone refractory, chemotherapy would be substituted. The objective of this study is the consideration of INTERMITTENT CHEMOTHERAPY’s role in patients’ survival and their quality of life.Materials & Methods: Since (1384,07,07), 25 patients with Hormone Refractory PROSTATE CANCER that referred to Taleghani & Imam Reza hospital were enrolled in this study, and Taxotere, Mitoxantrone and Navalbine were prescribed along with Estramustin 140 mg/m2 and Prednisolone 10 mg/BD for 4 days respectively(4, 5, 6) and the quality of life (QoL), toxicity and overall survival were evaluated. The most toxicity included grade 2 and 3 neuropathy and neutropenia that was compliant for patients. The overall survival was 22months.Conclusion: INTERMITTENT CHEMOTHERAPY in elderly patients with hormone refractory PROSTATE CANCER provides compliant toxicity and improvement of QoL and overall survival.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    AZNAB, MOZAFFAR, SAMADZADEH, BAHRAM, MORADI, ASSAD, BARDIDEH, ABDOL ROSOL, HOSEINI, JAMAL, & KAVIANI MOGHADAM, KAZHAL. (2011). THE ROLE OF INTERMITTENT CHEMOTHERAPY IN THE SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), 5(3), 21-23. SID. https://sid.ir/paper/313393/en

    Vancouver: Copy

    AZNAB MOZAFFAR, SAMADZADEH BAHRAM, MORADI ASSAD, BARDIDEH ABDOL ROSOL, HOSEINI JAMAL, KAVIANI MOGHADAM KAZHAL. THE ROLE OF INTERMITTENT CHEMOTHERAPY IN THE SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)[Internet]. 2011;5(3):21-23. Available from: https://sid.ir/paper/313393/en

    IEEE: Copy

    MOZAFFAR AZNAB, BAHRAM SAMADZADEH, ASSAD MORADI, ABDOL ROSOL BARDIDEH, JAMAL HOSEINI, and KAZHAL KAVIANI MOGHADAM, “THE ROLE OF INTERMITTENT CHEMOTHERAPY IN THE SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER,” INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), vol. 5, no. 3, pp. 21–23, 2011, [Online]. Available: https://sid.ir/paper/313393/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button